Vera Therapeutics, Inc. (VERA)
After hours:
| Previous Close | 34.89 |
| Open | 34.90 |
| Bid | 35.55 x 100 |
| Ask | 35.80 x 100 |
| Day's Range | 34.34 - 35.80 |
| 52 Week Range | 9.24 - 50.78 |
| Volume | |
| Avg. Volume | 916,067 |
| Market Cap | 1.949B |
| Beta (5Y Monthly) | 1.00 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.01 |
| Earnings Date | Aug 08, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 56.33 |
GlobeNewswireVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., July 05, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on July 1, 2024, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of a non-qualified stock option to purchase 160,000 shares of Class A common stock to David Johnson, Vera’s new Chief Operating Officer, under Vera’s 2024 Inducement Plan. Vera also announced that on July 2, 2024, the Compensation Committee granted additional inducement awards
- GlobeNewswire
Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer
BRISBANE, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of David L. Johnson as Chief Operating Officer, effective immediately. “We are excited to have David join our executive team at this important time for our clinical program of atacicept for the treatment of IgAN. W
- GlobeNewswire
Vera Therapeutics Appoints Christy J. Oliger to Board of Directors
BRISBANE, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Christy J. Oliger to its board of directors, effective June 7, 2024. Ms. Oliger brings over 30 years of experience in the biopharmaceutical industry, including being recognized for building highly effective team
